经皮胆管内射频消融(PERFA)治疗不可切除性胆管癌
回顾性分析8例不可切除性肝内/肝门部胆管癌患者接受经皮胆管内射频消融(Habib™ EndoHPB探头)的结果:技术成功率100%,临床成功率87.5%,无重大操作相关不良事件,AST显著下降(P=0.005),总胆红素下降未达统计学显著(P=0.187)。
要点
- 技术成功率100%(8/8),临床成功率87.5%(7/8),无重大操作相关不良事件包括血管并发症。
- 射频消融后总胆红素从5.5±7.6 mg/dL降至1个月时2.7±2.7 mg/dL,P=0.187,未达统计学显著。
- 引流管更换间隔从消融前1-3周延长至消融后4-8周,3例(37.5%)实现引流管内化。
核心结论
- 经皮胆管内射频消融使用Habib探头在不可切除性胆管癌中安全、技术可行,并与良好的实验室和临床结局相关。
研究设计与样本
- 回顾性研究,纳入8例不可切除性肝内/肝门部胆管癌患者(平均年龄59.9±6.2岁,男女各4例),于2022年1月至2025年6月接受经皮胆管内射频消融。
诊断标准与关键数值
- 临床成功定义为基线胆红素在1个月内降低≥50%,且14天内症状缓解或胆道梗阻相关临床参数改善,观察到7例(87.5%)达到临床成功。
临床应用与阅片要点
- 经皮胆管内射频消融可作为不可切除性胆管癌的姑息性介入手段,术后引流管更换间隔延长,部分患者可实现引流管内化。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
RATIONALE AND OBJECTIVES: Cholangiocarcinoma (CCA) is an aggressive malignancy often diagnosed at an advanced stage, precluding curative resection. In such patients, palliative interventions to relieve biliary obstruction are critical. Endobiliary radiofrequency ablation (RFA) using the Habib™ EndoHPB probe has been explored as an adjunct to improve biliary patency, though its percutaneous application and complication rate remain underexplored.
MATERIALS AND METHODS: We retrospectively reviewed eight patients (mean age: 59.9 ± 6.2 years; four males, four females) with unresectable intrahepatic/perihilar CCA who underwent percutaneous endobiliary RFA between January 2022 and June 2025. Outcomes included technical and clinical success, laboratory trends, adverse events, and interventional radiology (IR) service utilization.
RESULTS: Technical success was achieved in all patients (100%). Clinical success, defined as ≥50% bilirubin reduction from baseline within one month, and either symptom resolution within 14 days or improvement in biliary obstruction-related clinical parameters, was observed in seven patients (87.5%). No major procedure-related adverse events were noted, including vascular complications, despite endobiliary ablation. Following RFA, mean total bilirubin decreased from 5.5 ± 7.6 mg/dL to 2.7 ± 2.7 mg/dL at one month (p = 0.187). Aspartate aminotransferase (AST) declined from 85.9 ± 48.1 U/L to 59.7 ± 39.5 U/L (p = 0.005), and alanine aminotransferase (ALT) decreased from 104.7 ± 76.2 U/L to 56.1 ± 50.8 U/L (p = 0.054). The frequency of drain exchanges improved, with intervals extending from 1-3 weeks pre-RFA to 4-8 weeks post-RFA. Over a mean follow-up of 398.6 ± 562.3 days, three patients (37.5%) achieved drain internalization, while two deaths were attributed to disease progression.
CONCLUSION: Percutaneous endobiliary RFA with the Habib probe is safe, technically feasible, and associated with favorable laboratory and clinical outcomes in unresectable CCA.
引用
- Iqbal S, Hegde K, Arellano R, et al. Percutaneous Endobiliary Radiofrequency Ablation (PERFA) for Unresectable Cholangiocarcinoma. Acad Radiol. 2026. PMID: 41832084. doi:10.1016/j.acra.2026.02.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。